Quote:

---

While these experiments are underway, with data expected in the next several weeks, we are concurrently putting together the necessary orphan regulatory expertise to apply for Orphan Drug Designation (ODD) with the FDA. We expect to be in a position to file for ODD with the FDA for MANF in Retinitis Pigmentosa shortly after receiving the final data sets over the summer.

---